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To the editor:
We have read with interest the case report by Terijian and
colleagues and the comment from Brodsky et al. [1, 2].
We fully agree with the authors that succinylcholine-
associated myalgia might be a serious issue for many patients,
especially for morbidly obese patients. But we were a little bit
surprised about the authors’ opinion that there are no proven
strategies to reduce succinylcholine-associated myalgia sig-
nificantly. The authors have cited a meta-analysis by
Schreiber et al. that was published in 2005 in Anesthesiology
[3]. In this article it has been shown that the relative risk of
postoperative myalgia can be reduced significantly by using
a pretreatment with low-dose non-depolarizing neuromus-
cular blockers or sodium channel blockers such as lidocaine.
Currently, the paper represents the best available evidence
on the prevention of succinylcholine-associated myalgia.
Furthermore, we agree that sugammadex, a new binding
agent for the reversal of rocuronium and vecuronium, will
improve the safety profile of these agents but we are not
convinced that this will be the solution of all of our
problems. In case of a rapid sequence induction, the
anesthesiologist wants optimal intubation conditions within
seconds and in this specific situation succinylcholine still
seems to be superior compared to high-dose rocuronium—
according to a recent systematic review that was very well
done by Perry et al. [4].
The dilemma of systematic reviews and meta-analyses
might be that they cannot focus onto specific patient popu-
lations. This could be seen as a limitation of evidence-based
approaches. On the other hand, it represents the best way—
unless the contrary has been proven.
Another aspect emerges from this case report. After
dramatic improvements in clinical anesthesia during the last
50 years, a "dirty drug" that may cause potentially fatal
complications such as malignant hyperthermia or hyper-
kalemia still represents the "gold standard" for rapid
sequence induction. Surely, a non-depolarizing agent with
a comparable pharmacological profile but no side effects
would be the best replacement. Unfortunately, it has not
been found yet.
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